August 2, 2012
Citing the "emergence of a serious safety issue," Bristol-Myers Squibb Co. said Wednesday it was voluntarily suspending the Phase II study of a hepatitis C drug candidate, BMS-986094. Earlier this year, BMS paid $2.5 billion to acquire Inhibitex Inc., the company that developed the nucleotide polymerase inhibitor formerly known as INX-189. "The cause of the safety issue and any potential relationship to the study drug are unknown at this time," BMS said in a statement. The company currently is assessing all the study patients and will decide on next steps following an evaluation of patient data.
Wall Street Journal
08.02.2012; Saabira Chaudhuri
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|